Rituximab, Intravitreal Bevacizumab and Laser Photocoagulation for Treatment of Macrophage Activation Syndrome and Retinal Vasculitis in Lupus: A Case Report (CROSBI ID 321052)
Prilog u časopisu | prikaz, osvrt, kritika | međunarodna recenzija
Podaci o odgovornosti
Ikić Matijašević, M ; Kilić, P ; Ikić, L ; Galić, I ; Brzović Šarić, V ; Galić, E
engleski
Rituximab, Intravitreal Bevacizumab and Laser Photocoagulation for Treatment of Macrophage Activation Syndrome and Retinal Vasculitis in Lupus: A Case Report
Systemic lupus erythematosus (SLE) most commonly manifests as mild to moderate disease with severe manifestations such as diffuse alveolar hemorrhage, central nervous system vasculitis, macrophage activation syndrome (MAS) or retinal vasculitis (RV) with visual disturbances occurring in a significantly smaller proportion of patients, most of whom have a poor outcome. Macrophage activation syndrome and RV are insufficiently early and rarely recognized presentations of lupus —consequently there are still no treatment recommendations. Here we present the course of diagnosis and treatment of a patient with an SLE flare that resulted in both life-threatening disease (MAS) and vision-threatening disease (RV). The patient was successfully treated with systemic immunosuppressives, a high dose of glucocorticoids and rituximab (RTX), in parallel with intraocular therapy, intravitreal bevacizumab (BEV) and laser photocoagulation.
systemic lupus erythematosus ; retinal vasculitis ; macrophage activation syndrome ; hemophagocytic lymphohistiocytosis ; rituximab ; bevacizumab ; anti-VEGF ; laser photocoagulation
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
24
2023.
2594
9
objavljeno
1422-0067
https://doi.org/10.3390/ijms24032594
Povezanost rada
Farmacija, Kliničke medicinske znanosti